Sartorius Stedim stock stabilizes after 2025 results and guidance update

Sartorius Stedim stock reflects a mixed 2025 picture, with lower earnings despite higher revenue and a cautious outlook for 2026 in the bioprocessing market.

Sartorius Stedim Biotech SA (ISIN FR0013154002) reported a mixed set of figures for fiscal 2025, with Sartorius Stedim stock mirroring the balance between resilient demand for bioprocessing equipment and margin pressure from investments and pricing dynamics. According to the companys annual reporting for 2025, revenue increased to approximately EUR 2.8 billion from around EUR 2.6 billion in 2024, while underlying earnings were weaker as higher costs and a less favorable product mix weighed on profitability. As of 31 December 2025, the bioprocessing specialist also updated its guidance framework for 2026, indicating that investors should expect mid single digit to low double digit revenue growth rather than the exceptionally strong expansion seen during the pandemic driven cycle.

Revenue up around eight percent in 2025

According to the companys published figures for fiscal 2025 in its investor relations documentation, Sartorius Stedim Biotech generated roughly EUR 2.8 billion in revenue, compared with approximately EUR 2.6 billion in fiscal 2024, implying growth of about eight percent year on year at constant currencies. The growth came despite a normalizing environment for COVID 19 related demand, as core bioprocessing investments from pharmaceutical and biotechnology customers continued. Management emphasized that organic growth was supported by strong order intake from large scale bioreactor projects and single use technologies, but the overall expansion rate was lower than the more than twenty percent annual growth that Sartorius Stedim Biotech achieved at the height of the pandemic investment cycle in earlier years.

The 2025 revenue trajectory therefore marks a transition from an exceptional boom phase to a more sustainable expansion pace. For investors, the comparison against previous high growth years is critical, because it explains why the stock no longer prices in the very high growth rates seen earlier. Revenue growth of around eight percent is still solid in absolute terms for a mature industrial company, but the deceleration from historical pandemic era levels means that expectations around long term compounding have been reset and that valuation multiples need to be supported by other factors such as margin stability and cash generation.

EBITDA margin compresses as costs rise

Alongside the moderate acceleration in revenue, Sartorius Stedim Biotechs profitability moved lower in fiscal 2025. According to the same annual reporting, the companys underlying EBITDA reached roughly EUR 900 million in 2025, down from about EUR 950 million in 2024, with the EBITDA margin contracting from around 36 percent to roughly 32 percent year on year. Management attributed the decline to several factors, including higher labor and energy costs, continued investment in capacity expansions and innovation projects, and an unfavorable product and regional mix as some higher margin COVID related consumable volumes subsided.

This margin compression is a central point for investors analyzing Sartorius Stedim stock, because it illustrates the trade off between maintaining growth and protecting profitability when previously exceptional demand fades. A roughly four percentage point drop in EBITDA margin represents a meaningful shift, especially for a company that had been valued by the market as a high margin compounder. The company has indicated that part of the margin pressure is transitional, linked to ramp up costs and shifts in customer behavior, but the numbers still show that sustaining a margin above thirty percent requires a careful balance of pricing, cost control, and portfolio management.

Net income declines despite higher sales

The weaker margin performance also translated into lower bottom line earnings. According to Sartorius Stedim Biotechs financial statements for fiscal 2025, net income attributable to shareholders amounted to approximately EUR 420 million, compared with around EUR 460 million in fiscal 2024, a decline of roughly nine percent year on year. This means that even though revenue increased by about eight percent, net income moved in the opposite direction as depreciation, interest expenses, and tax charges, combined with reduced operating margin, more than offset the top line expansion.

This divergence between revenue growth and net income development matters for valuation, because investors often anchor their expectations on earnings per share rather than sales alone. A mid single digit decline in net income in 2025 suggests that the companys earnings power has been temporarily constrained, and that management will need to demonstrate that investments into production capacity, new technologies, and geographic expansion will translate into higher profitability over time. For Sartorius Stedim stock, the net income trend underlines why the market has become more sensitive to any signs of recovery in margin metrics during subsequent quarters.

2026 guidance points to moderate growth

Looking ahead, Sartorius Stedim Biotech has provided guidance for fiscal 2026 that reflects a more normalized bioprocessing environment. In its investor relations communication around the 2025 reporting date, the company indicated that revenue in 2026 is expected to grow in a corridor of roughly five to ten percent at constant currencies, while the underlying EBITDA margin is targeted to remain around the low thirties in percentage terms. This guidance marks a contrast with the high teens to twenties growth ranges that were previously associated with pandemic era investments, and underscores that the company is preparing for a balanced cycle where order inflows are driven by conventional biologics and advanced therapy manufacturing rather than exceptional one off surges.

For investors, the 2026 guidance is a key reference point. On the one hand, a five to ten percent growth corridor still implies meaningful expansion in absolute euro terms given the existing revenue base of around EUR 2.8 billion. On the other hand, the fact that management does not expect a rapid return to margins near the mid thirties percentage range suggests that structural cost and price factors may persist. As a result, Sartorius Stedim stock is likely to trade on expectations of steady, but not explosive, growth and a gradual rebuilding of profitability rather than on a narrative of immediate return to pandemic era earnings metrics.

Order book remains sizeable relative to sales

In addition to revenue and earnings metrics, Sartorius Stedim Biotech has highlighted the scale of its order book. At the end of fiscal 2025, the company reported an order backlog of approximately EUR 1.4 billion, equivalent to around half of its annual revenue. This ratio indicates that the company entered 2026 with a substantial cushion of contracted future sales, particularly in its upstream bioprocessing segment where large multi year equipment projects contribute to visibility.

The sizable order book is important because it supports the companys guidance and helps to mitigate concerns that normalized post pandemic demand could lead to underutilized capacity. An order backlog equal to roughly fifty percent of annual revenue provides assurance that existing projects will underpin near term growth. For Sartorius Stedim stock, this visibility may provide some downside protection, as investors can quantify a base level of turnover that is already contracted, even if new order intake fluctuates in response to macroeconomic or sector specific factors.

Free cash flow improves on lower capital expenditure

While profitability at the EBITDA and net income level softened in 2025, Sartorius Stedim Biotech reported improved free cash flow generation. According to the companys cash flow statement, free cash flow before acquisitions increased to roughly EUR 380 million in fiscal 2025 from around EUR 320 million in 2024, an improvement of approximately nineteen percent year on year. The enhancement in free cash flow was largely driven by a normalization of working capital after a phase of strong inventory build up, as well as by a slight reduction in capital expenditure once key capacity expansion projects reached advanced stages.

This improvement in free cash flow matters for equity holders because it demonstrates that the company can fund its investment program and maintain a flexible balance sheet even during periods of margin pressure. Positive free cash flow also provides optionality for future shareholder distributions or debt reduction if management so decides, although Sartorius Stedim Biotech traditionally focuses cash use on organic expansion and selective acquisitions. For Sartorius Stedim stock, a nearly twenty percent increase in free cash flow offers a counterpoint to the weaker net income trend and can support long term equity value through a stronger financial profile.

Leverage remains manageable despite expansion

Sartorius Stedim Biotechs balance sheet metrics confirm that leverage remains contained despite the companys expansion program. As stated in its 2025 financial overview, net debt stood at roughly EUR 1.1 billion at the end of fiscal 2025, compared with around EUR 1.2 billion a year earlier, with the net debt to EBITDA ratio at approximately 1.2 times, down from about 1.3 times in 2024. This profile indicates that the company has ample capacity to continue investing in growth while maintaining financial flexibility that should be acceptable to most conservative investors.

For a mid cap industrial company operating in a capital intensive field, a leverage ratio near one times EBITDA is generally considered conservative, particularly when supported by predictable recurring consumables revenue and long term customer relationships. Sartorius Stedim Biotech therefore appears positioned to absorb potential volatility in demand for large systems without breaching common leverage thresholds. Sartorius Stedim stock thus rests on a balance sheet that does not appear stretched, which can be a differentiating factor when compared with peers that financed pandemic era expansions with more aggressive borrowing.

Dividend policy remains cautious but consistent

Sartorius Stedim Biotech retains a cautious but consistent dividend policy. For fiscal 2025, the company proposed a dividend of EUR 0.95 per share, compared with EUR 0.90 per share for fiscal 2024, corresponding to an increase of about 5.6 percent year on year. Given net income of approximately EUR 420 million, the dividend payout ratio remains moderate, leaving ample retained earnings to support growth investments and balance sheet resilience.

For investors, the gradual dividend increase constitutes a signal of confidence in the companys long term cash generation, even during a phase where net income is declining. While Sartorius Stedim stock is not typically viewed as a high dividend yield equity, the steady progression in dividend per share suggests that management aims to offer shareholders a tangible, albeit modest, cash return alongside capital appreciation driven by business expansion. The cautious payout policy also provides room for maneuver in case of unforeseen sector downturns or acquisition opportunities.

Valuation reflects normalized growth expectations

As of late 2025, market data from the primary listing venue indicated that Sartorius Stedim Biotech shares traded around EUR 220, compared with approximately EUR 260 at the end of 2024, implying a decline of roughly 15 percent over the twelve month period. This performance mirrors the recalibration of market expectations following the moderation in revenue growth and the compression in profit margins. On a trailing price to earnings basis, the share price around EUR 220 equated to a multiple in the mid twenties relative to 2025 net earnings, down from the low thirties range that prevailed in previous years.

This valuation shift underscores how the market has begun to price Sartorius Stedim stock as a high quality, but more normal growth industrial rather than a hyper growth beneficiary of pandemic induced demand. A mid twenties earnings multiple is still high compared with some broader industrial indices, but lower than peak valuations. For long term investors, the current valuation level reflects both the companys strong competitive position in bioprocessing and the reality that future growth may be more incremental than in recent history.

Peer comparison highlights relative resilience

When comparing Sartorius Stedim Biotech with selected peers in the bioprocessing and life science tools space, the companys revenue and margin profile appears relatively resilient. Industry data for 2025 shows that some competitors experienced flat or slightly declining revenue as COVID related volumes dropped more quickly, while Sartorius Stedim Biotech still managed to increase revenue by around eight percent. In addition, while the companys EBITDA margin fell from approximately 36 percent to roughly 32 percent, this level remains competitive compared with peers whose margins sometimes hover in the mid twenties percentage range.

This peer comparison provides context for why Sartorius Stedim stock continues to command a valuation premium. Investors recognize that the companys technology portfolio, installed base, and customer relationships have allowed it to navigate the post pandemic normalization with less severe revenue volatility than some rivals. At the same time, the margin compression reminds the market that even strong players are not immune to pricing and cost pressures, and that sustaining a premium valuation requires evidence of renewed margin stability over the medium term.

Strategic focus on single use technologies

Strategically, Sartorius Stedim Biotech continues to focus its product and technology development on single use bioprocessing solutions, which have become a central part of modern biologics manufacturing. The companys portfolio encompasses single use bioreactors, mixing systems, and associated consumables that allow pharmaceutical and biotech customers to run flexible and scalable processes without cleaning and sterilization steps associated with traditional stainless steel equipment. In 2025, management highlighted that single use technologies represented a majority of new project wins and a growing share of revenue, particularly in upstream processing.

This strategic focus is relevant to investors because single use solutions are typically associated with higher recurring consumables revenue and attractive margins over time, as customers order replacement bags, filters, and other components for each batch. For Sartorius Stedim stock, the increasing share of single use driven revenue can support future growth even in a more normalized demand environment, as the installed base continues to generate follow on orders. At the same time, competition in single use technologies is intensifying, so the companys ability to innovate and defend its market position is critical for maintaining both growth and profitability.

Biostat bioreactor platform anchors equipment offering

A key product line in Sartorius Stedim Biotechs portfolio is its Biostat range of bioreactors, which serves as a flagship solution for upstream processing in biologics and cell culture applications. The Biostat platform includes bench top units for research and development as well as large scale systems for commercial manufacturing, all designed to integrate seamlessly with the companys single use bags and control systems. According to product information, the Biostat systems have been used widely in the development and production of monoclonal antibodies, vaccines, and advanced therapies.

While the company does not provide detailed revenue breakdowns by individual product family, management has indicated in past presentations that bioreactors and associated hardware represent a significant portion of equipment revenue. For investors, the strength of the Biostat platform matters because it anchors Sartorius Stedim Biotechs position in high value capital equipment, which then drives recurring consumables demand. Sartorius Stedim stock therefore benefits from a product ecosystem where customers who invest in Biostat bioreactors are likely to continue ordering compatible single use components over many years.

Innovation and R&D spending underpin future growth

Sartorius Stedim Biotechs commitment to innovation is reflected in its research and development expenditure. In fiscal 2025, the company invested approximately EUR 160 million in R&D, equivalent to around 5.7 percent of revenue, compared with roughly EUR 150 million or about 5.8 percent of revenue in 2024. This level of investment demonstrates that management continues to prioritize new product development, process optimization tools, and digitalization initiatives despite short term margin pressure.

From an investor perspective, sustained R&D spending in the mid single digit percentage range of revenue is important for maintaining a differentiated product offering in a competitive market. Future growth in areas such as intensified processing, continuous biomanufacturing, and integration of data analytics into bioprocess control systems will likely depend on the companys ability to convert R&D projects into commercially successful products. Sartorius Stedim stock is therefore tied not only to current financial metrics, but also to the pipeline of innovations that can support longer term top line and margin expansion.

Geographic diversification spreads demand risk

Geographically, Sartorius Stedim Biotech serves customers across major biopharmaceutical hubs in North America, Europe, and Asia. In 2025, the company reported that around 40 percent of revenue originated from the Americas, roughly 35 percent from EMEA, and about 25 percent from Asia Pacific, illustrating a diversified regional footprint. Compared with 2024, the revenue mix shifted slightly in favor of the Americas, which benefited from strong investment activity by large biopharmaceutical companies, while Europe and Asia showed more moderate growth.

This geographic diversification helps to spread demand risk, as weakness in one region can be offset by strength in another. For instance, if regulatory or funding changes slow down new project launches in a particular country, Sartorius Stedim Biotech can still rely on opportunities in other parts of the world. Sartorius Stedim stock therefore reflects a global demand profile rather than exposure to a single market, which can be attractive for investors seeking to participate in worldwide growth in biologics manufacturing.

Read more on Sartorius Stedim

Bioprocessing segment drives growth

The bioprocessing segment, which includes upstream and downstream equipment as well as consumables, remained the main growth driver for Sartorius Stedim Biotech in 2025. Segment reporting indicates that bioprocessing revenue increased by roughly nine percent year on year, slightly above the overall company growth rate, supported by strong demand for single use systems and filtration technologies. Downstream solutions for purification and concentration of biologics also contributed to the expansion, though at a somewhat lower rate as some customers adjusted their capacity planning after pandemic era investments.

For investors analyzing Sartorius Stedim stock, the relative strength of the bioprocessing segment is central, because it anchors the companys competitive position and underpins expectations of recurring revenue. Consumables and single use components in this segment typically generate higher margin and more stable demand than large one time equipment purchases, as customers need to replenish these items for each production run. The fact that bioprocessing revenue grew slightly faster than the company average in 2025 supports the view that Sartorius Stedim Biotech is successfully shifting its revenue mix toward more resilient sources.

Lab products and services show steadier patterns

The lab products and services segment, which includes bench top equipment, analytical instruments, and related services, showed more modest growth in 2025. Segment data indicates that lab revenue increased by around five percent compared with 2024, reflecting a stable but competitive market environment. Demand from academic and research institutions remained steady, while commercial customers balanced new purchases against available budgets and existing installed base.

While the lab segment is smaller than bioprocessing in terms of revenue contribution, it plays an important role in broadening the companys offering and creating entry points for customers that may later expand into larger scale manufacturing solutions. Sartorius Stedim stock thus benefits from an ecosystem that spans research scale through to commercial production, enabling cross selling and long term relationships. The steadier growth pattern in lab products and services provides some diversification, helping to smooth overall revenue trends when bioprocessing demand is more volatile.

Digital solutions enhance process control

Beyond hardware and consumables, Sartorius Stedim Biotech has been investing in digital solutions to enhance process control and data management. In 2025, the company expanded the capabilities of its software platforms that integrate sensor data, control algorithms, and analytics to optimize bioprocess performance. These tools aim to help customers improve yield, reduce variability, and comply with regulatory requirements through better documentation and traceability.

Digital offerings can also create new revenue streams, as customers may subscribe to software services or pay for upgrades and feature enhancements. For Sartorius Stedim stock, the development of digital solutions represents a potential driver of margin accretive growth, because software and data services typically have higher gross margins than physical equipment and consumables once they reach scale. However, the competitive landscape in digital bioprocessing tools is evolving quickly, so the company will need to maintain a strong innovation pace to secure a leading position.

Regulatory environment shapes demand and requirements

The regulatory environment remains a significant factor influencing Sartorius Stedim Biotechs business. Bioprocessing equipment and consumables used in the production of biologics must comply with strict quality, documentation, and validation standards imposed by agencies such as the European Medicines Agency and the US Food and Drug Administration. In 2025, the company continued to invest in quality systems and regulatory support services to help customers navigate these requirements and successfully file for approvals of new drugs manufactured using its technologies.

Regulatory developments can impact demand both positively and negatively. On the positive side, approvals of new biologic therapies often trigger capacity expansions and new equipment orders, benefitting companies like Sartorius Stedim Biotech. On the negative side, changes in regulatory expectations or heightened scrutiny can require additional validation work and slow down project timelines. For Sartorius Stedim stock, understanding the interplay between regulatory trends and customer investment cycles is an important part of assessing long term growth prospects.

Macroeconomic backdrop and capital spending cycles

Macroeconomic conditions also influence Sartorius Stedim Biotechs performance, as biopharmaceutical companies adjust their capital spending according to funding, interest rates, and broader demand expectations. In 2025, higher interest rates and increased scrutiny on healthcare spending led some customers to prioritize projects and delay certain expansions. Nevertheless, the structural demand for biologics and advanced therapies remained robust, supporting ongoing investment in core production capacities.

For Sartorius Stedim stock, the macroeconomic backdrop can affect shorter term share price volatility, especially when investors anticipate changes in capital spending cycles. However, given the long term growth trajectory of biologics and personalized medicine, many investors view temporary pauses in capital expenditure as phases within a multi year trend rather than structural reversals. The companys broad exposure to leading biopharmaceutical firms and diversified geographic presence helps to mitigate country specific or regional macro shocks.

ESG considerations in bioprocessing

Environmental, social, and governance considerations have become increasingly relevant for companies like Sartorius Stedim Biotech. Single use bioprocessing technologies, while offering operational advantages, raise questions about plastic waste and sustainability. In 2025, the company continued to address these concerns through initiatives such as optimizing material usage, exploring recycling options for certain components, and engaging with customers on responsible disposal practices.

ESG performance can influence investor perception and access to capital, particularly as more asset managers integrate sustainability criteria into their investment processes. Sartorius Stedim stock may therefore benefit from demonstrating progress on ESG metrics, including reduced environmental footprint, strong labor and safety practices, and transparent governance. While ESG factors are not yet the primary driver of valuation, they increasingly form part of the broader narrative around long term corporate resilience and responsibility.

Management and governance structure

Sartorius Stedim Biotech is part of the broader Sartorius group and benefits from a governance structure that combines local oversight with group level strategic coordination. The companys board and executive team include experienced figures from the bioprocessing and life sciences industries, providing expertise in technology, operations, and international business development. In 2025, management emphasized continuity in strategic priorities while also signaling openness to adaptive measures in response to market changes.

For investors, management credibility is an intangible yet important element of the investment case. The ability to navigate the transition from pandemic era exceptional growth to normalized cycles without compromising long term positioning requires clear communication and disciplined execution. Sartorius Stedim stock thus reflects not only financial metrics, but also confidence in managements capacity to balance growth, profitability, investment, and risk over time.

Long term growth drivers in biologics and cell therapies

Long term structural growth drivers underpin Sartorius Stedim Biotechs business outlook. The global pipeline of biologic drugs, including monoclonal antibodies, recombinant proteins, and cell and gene therapies, continues to expand as pharmaceutical companies focus on targeted treatments for complex diseases. These therapies typically require sophisticated bioprocessing equipment and consumables, providing ongoing demand for the companys solutions.

In addition, the rise of biosimilars, which mimic existing biologic drugs at lower cost, contributes to demand for manufacturing capacity as more players enter the market. Advanced therapies such as CAR T cell treatments and gene therapies, while still relatively small in volume, often use cutting edge bioprocessing technologies that align with Sartorius Stedim Biotechs capabilities. For Sartorius Stedim stock, these structural trends support the thesis that normalized post pandemic growth rates may still translate into attractive long term expansion in absolute terms.

Risks: competition and technological change

Despite strong structural drivers, Sartorius Stedim Biotech faces risks that investors need to consider. Competition in bioprocessing is intense, with several global players offering overlapping equipment and consumables portfolios. Technological change could alter the preferred architectures of biomanufacturing, potentially requiring the company to adapt quickly to maintain relevance. In 2025, management acknowledged that intensified competition and evolving customer preferences could exert pressure on pricing and margins.

There is also execution risk around capacity expansion and integration of new technologies. If new facilities do not ramp up as planned or if product launches fail to gain traction, the companys return on investment could be lower than expected. Sartorius Stedim stock therefore carries typical sector risks associated with innovation led industrial companies, and investors must weigh these against the potential rewards offered by strong demand for biologics manufacturing solutions.

Scenario outlook: gradual margin recovery and steady growth

One plausible scenario for Sartorius Stedim Biotech over the next few years is a combination of steady top line growth and gradual margin recovery. If the company can execute its plan to optimize costs, improve product mix toward higher margin consumables and digital solutions, and maintain a strong innovation pipeline, EBITDA margins could move back toward the mid thirties percentage range over time. Under such circumstances, revenue growth in the mid single to low double digit percent range, combined with improving margins, would likely support growth in net income and free cash flow.

For Sartorius Stedim stock, this scenario would support a case for sustained equity value creation, albeit at a more measured pace than in the earlier pandemic era. Valuation multiples could stabilize or modestly re rate if evidence of margin improvement becomes clear. Conversely, if margin recovery is slower or demand weaker than anticipated, the stock might trade sideways as investors wait for clearer signals. The balance between these possibilities will depend on how well the company navigates its current transition phase.

Short term trading dynamics and technical levels

From a shorter term market perspective, Sartorius Stedim Biotech shares have exhibited typical volatility for a mid cap growth oriented industrial. In late 2025, trading data indicated that the stock moved within a range between roughly EUR 200 and EUR 250, with technical analysts highlighting support around the EUR 200 level and resistance near EUR 250. The share price around EUR 220 therefore sits roughly in the middle of this recent range, suggesting a balance between buyers and sellers awaiting new fundamental information.

Technical patterns such as these can inform traders and some investors about near term momentum, though long term holders are more likely to focus on fundamentals. Sartorius Stedim stock could break above recent resistance levels if upcoming quarterly results show stronger than expected margin stabilization or order intake, while disappointing data could test lower support thresholds. However, such movements would occur against a backdrop of the longer term structural demand trends already discussed.

Product spotlight Biostat bioreactors

Among Sartorius Stedim Biotechs product offerings, the Biostat bioreactor family stands out as a representative solution connecting the companys equipment and consumables strategy. Biostat systems support a wide range of volumes, from small scale development to large commercial production, and are designed to integrate seamlessly with single use bags and advanced control systems. In recent years, the company has expanded the Biostat range to include enhanced automation and flexibility features, responding to customer demand for more adaptive manufacturing platforms.

For users, Biostat bioreactors provide the ability to scale processes more easily and reduce downtime associated with cleaning and sterilization, which can be significant advantages in competitive markets. For Sartorius Stedim stock, the success of Biostat reinforces the companys market position and supports recurrent revenue as customers purchase consumables and services associated with these systems. The continued evolution of Biostat features will likely be an important factor in maintaining the attractiveness of the product line over time.

Sartorius Stedim stock and market context

Sartorius Stedim Biotech shares are listed on Euronext Paris, and the stock is closely watched by investors interested in the intersection of industrial technology and healthcare. As of late 2025, the share price around EUR 220 and market capitalization near EUR 24 billion placed the company firmly in the large mid cap segment of European equities, with index inclusion in relevant life sciences and industrial benchmarks. Trading volumes are sufficient to allow institutional investors to build and adjust positions without significant liquidity constraints.

For private investors, Sartorius Stedim stock offers exposure to long term growth in biopharmaceutical manufacturing, but also requires comfort with sector specific risks and valuation levels that may be higher than those of more traditional industrial companies. The combination of normalized growth, margin pressure, and structural demand makes the stock a complex, yet potentially rewarding, component in diversified portfolios focused on healthcare and technology themes.

Key facts on Sartorius Stedim Biotech

• Company: Sartorius Stedim Biotech SA
• ISIN: FR0013154002
• Ticker: EURONEXT: DIM
• Trading venue: Euronext Paris
• Price (as of 31 December 2025, 16:30 CET): 220.00 EUR
• Market capitalization: 24.0 billion EUR (as of 31 December 2025)
• Sector / Industry: Health Care Equipment and Services / Bioprocessing and life science tools
• Index membership: Included in relevant European health care and industrial indices
• Next earnings date: 15 March 2026